openPR Logo
Press release

$3 Billion Suicidal Depression Market May Soon be Accessible via FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

08-11-2025 10:48 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Getnews

/ PR Agency: CAP, LLC
$3 Billion Suicidal Depression Market May Soon be Accessible via

Image: https://www.globalnewslines.com/uploads/2025/08/1754917343.jpg

$NRXP Has $7.8 Million for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD

* Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.

* Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).

* FDA Fast Track Designation for NRX 100 for Suicidal Ideation in Patients with Depression, Including Bipolar Depression.

* Designation Includes an FDA Determination That NRX-100 has Potential to Address an Unmet Need, Based on FDA's Assessment of Data Submitted.

* 13 Million Adults Seriously Consider Suicide Each Year, According to the CDC, 3.2 Million Make a Plan to Commit Suicide.

* Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA).

* Actions Taken to Request the Removal of Benzethonium Chloride from Ketamine Products in Favor of the Company's Safer and Superior Options.

* $7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions with Universal Capital, LLC.

* Accepted Non-Binding Potential Terms to License and Distribute NRX-100 Drug Providing Over $300 Million in Milestones Plus Tiered Double-Digit Royalties.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain

NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year.

FDA Fast Track Designation for NRX 100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression

On August 11th NRXP announced the US Food and Drug Administration (FDA) has granted Fast Track designation to its NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. This designation for NRX-100 as a standalone drug is a 10-fold expansion of the addressable population for NRX-100, compared to the designation granted in 2017 for NRX-100 in combination with NRX-101 (DCS/lurasidone) for treatment of Suicidal Bipolar Depression.

In granting the Fast Track designation, FDA made the determination that NRXP NRX-100 has the potential to address an unmet medical need, based on an assessment of the preliminary data contained in the Fast Track designation request. This determination of unmet medical need aligns with the eligibility requirements for the Commissioner's National Priority Voucher Program and for the FDA's Accelerated Approval Program.

NRXP has applied for a CNPV, which has the potential to substantially shorten the review cycle for NRX-100. Several well-controlled trials submitted to FDA in support of Fast Track Designation demonstrated a clinically meaningful and statistically significant reduction of suicidal ideation.

Regarding Fast Track designation, FDA's website states: A drug that receives Fast Track designation is eligible for some or all of the following:

More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval.

More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers

Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met.

Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA.

NRXP NRX-100 is poised to address the >$3 billion Suicidal Depression market in the US.

Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA)

On August 8th NRXP announced it has received final clearance and approval from the Florida Agency for Health Care Administration (AHCA) to proceed closing of its Dura Medical LLC acquisition, in connection with its change of ownership applications, a key regulatory step for closing. Dura is revenue generating and EBITDA positive.

Request to the Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products to Favor a Switch to Better Options

On August 4th NRXP announced its actions with the US Food and Drug Administration (FDA), seeking the removal of Benzethonium Chloride from ketamine sold in the United States. Benzethonium Chloride (BZT) is a preservative that is not Generally Recognized as Safe (GRAS) by the FDA for parenteral products and not Generally Recognized as Safe and Effective (GRASE) for topical products. The FDA no longer allows BZT to be used in hand cleansers and topical antiseptics and other products on the market today for safety concerns. The ketamine versions made by NRXP is BZT free and therefore presents a safer and superior option.

Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics

On June 26th NRXP announced the signing of a binding Letter of Intent to purchase a 49% interest in Cohen and Associates, LLC. Cohen is expected to serve as a foundational clinic for NRXP in the Sarasota-Bradenton region of western Florida.

Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

On June 23rd NRXP announced filing for the newly-announced FDA Commissioner's National Priority Voucher program on behalf of NRX-100, its patent-pending, preservative-free formulation of ketamine for intravenous use.

Strategic Investor Relations Partnership with astr partners

On June 16th NRXP announced a strategic investor relations partnership with astr partners, a boutique investor relations and capital advisory firm focused on the life sciences sector.

$7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions

On May 15th NRXP announced signing of a term sheet with Universal Capital, LLC to provide $7.8 million in acquisition capital to initiate subsidiary HOPE's planned national rollup of interventional psychiatry clinics, commencing with previously-announced acquisitions of Dura Medical, Kadima, and NeuroSpa. Together with proceeds of a previously announced strategic investment, this financing is anticipated to provide $10.3 million in acquisition capital.

For more information on $NRXP visit: https://www.nrxpharma.com/ [about:blank] and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: Send Email [http://www.universalpressrelease.com/?pr=3-billion-suicidal-depression-market-may-soon-be-accessible-via-fda-fast-track-designation-for-effective-nrx-100-drug-therapy-nrx-pharmaceuticals-inc-nasdaq-nrxp]
Phone: 484 254 6134
Address:1201 Orange Street Suite 600
City: Miami
State: Florida
Country: United States
Website: https://www.nrxpharma.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release $3 Billion Suicidal Depression Market May Soon be Accessible via FDA Fast Track Designation for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) here

News-ID: 4140698 • Views:

More Releases from Getnews

Inclusive Shapewear Defines CYSM's Growing Sisterhood of Support
Inclusive Shapewear Defines CYSM's Growing Sisterhood of Support
CYSM is a shapewear brand where women empower one another through supportive fashion, shared confidence, and collective strength. Rooted in community, the brand represents women helping women and celebrates diversity through inclusive shapewear, inviting every woman to feel supported, distinguished, and inspired in her journey. Image: https://www.globalnewslines.com/uploads/2025/08/5b5eac2a2dc61e9e461146b44631fbd9.jpg Video: https://www.youtube.com/embed/P68sQXzeDAo?si=yhTpt7xfMkSYH2kC The idea of shaping up has always carried many meanings, but at CYSM, it has grown into something more than a conversation about appearance.
CYSM Shapers Showcases New Shapewear Lineup to Usher in a New Era for Women Embracing Themselves Fully
CYSM Shapers Showcases New Shapewear Lineup to Usher in a New Era for Women Embr …
CYSM Shapers is a US-based manufacturer of shapewear products with over 30 years of industry presence and innovation. Image: https://www.globalnewslines.com/uploads/2025/08/968e474fb1ca1f30808973da2a19cd2c.jpg While showcasing the latest editions to its Fajas Collection [https://cysm.com/collections/best-body-shaper-hourglass-figure], the team behind CYSM Shapers [https://www.cysm.com] has expressed great pride after their products have helped thousands of women nationwide in embracing curves, boosting their body confidence and self-image. CYSM is a company with over 30 years of operating experience. They are known for
Seddy Expands National Retail Presence with Hair and Body Oils Made in the USA
Seddy Expands National Retail Presence with Hair and Body Oils Made in the USA
From kitchen beginnings to national shelves, Las Vegas-based Seddy grows steadily with clinically guided, plant-powered haircare now available on Amazon, Walmart, Etsy, and https://www.seddynaturals.com. Seddy, a clean beauty brand specializing in hair and body oils, is gaining national recognition as it expands across Amazon, Walmart, Etsy, and its official website, https://www.seddynaturals.com. Proudly made in the USA, the company has grown from small kitchen formulations into a trusted brand nationwide, built on
GCC's $6.4 Billion AI Surge Presents Opportunity to Address Misinformation and Strategic Communication Risk
GCC's $6.4 Billion AI Surge Presents Opportunity to Address Misinformation and S …
As GCC institutions scale digital infrastructure, strategic consultants call for stronger integration of enterprise resilience and information governance. Image: https://www.globalnewslines.com/uploads/2025/09/0ac76e4b78ed64f9c890679e6b4c2735.jpg New York - September 6, 2025 - With AI investment across the Gulf Cooperation Council (GCC) projected to exceed $6.4 billion by 2026, regional institutions have an opportunity not only to lead in innovation-but to strengthen their defenses against rising misinformation and strategic communication risk. According to recent market research reports, this surge

All 5 Releases


More Releases for NRX

Advancements on Multiple Fronts in $3 Billion Suicidal Depression Market, Highli …
Image: https://www.globalnewslines.com/uploads/2025/08/1755525181.jpg $NRXP Sees 10-Fold Market Expansion to 13 Million Americans for Bipolar Depression Alone. * Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain. * Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC). * FDA Fast Track Designation for NRX 100 for Suicidal Ideation in Patients with Depression, Including Bipolar Depression.
$300 Million in Milestones Plus Tiered Double-Digit Royalties from Accepted Term …
Image: https://www.globalnewslines.com/uploads/2025/03/1742217317.jpg $NRXP is Poised to Address Over $3 Billion Suicidal Depression Market in the US * Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain. * Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression * Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC). * New Drug Application for
Transforming Mental Health Treatments and Expanding Clinic Networks: NRx Pharmac …
Image: https://www.globalnewslines.com/uploads/2025/01/1737669812.jpg NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP), a clinical-stage biopharmaceutical leader, is at the forefront of addressing critical mental health challenges, including suicidal depression, bipolar disorder, and PTSD. Through groundbreaking therapeutics and strategic investments, the company aims to revolutionize care for millions while delivering significant returns for investors. A Breakthrough in Mental Health Treatment NRX-101, the company's flagship product, is an FDA-designated investigational Breakthrough Therapy targeting suicidal treatment-resistant bipolar depression and chronic
NRx Pharmaceuticals Highlights Breakthrough Oral Antidepressant's Efficacy in Re …
- Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD. - June Meeting of the American Society for Clinical Psychopharmacology Focused on Intravenous Ketamine and Intranasal S-Ketamine for Severe Depression and Suicidality. - Presenters from 3 Open Label Studies at the ASCP Suggested Intravenous Ketamine is Equivalent or has Advantages over Intranasal S-Ketamine. - NRXP Reached 9-Month Stability Point with its Ketamine Formulation (NRX-100) and Initiated
Final Clinical Trial Results Show Superior Safety and Efficacy for NRX-101; Plan …
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD. MOU Signed with Conversio Health with Immediate Plans to Ship IV Ketamine Product to Full Range of Customers via 503a and 503b Pharmacies. Clinical Trial Success in Proving a Statistically-Significant 76% Reduction in Akathisia in Participants Treated with NRX-101 Compared to Lurasidone. Company Plans to Seek Accelerated Approval of NRX-101 for Bipolar Depression and Akathisia and Broaden
Complicated Urinary Tract Infections (UTI) Pipeline Analysis (2023) Covering Cli …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 12+ key pharma and biotech companies are working on 12+ pipeline drugs in the Complicated Urinary Tract Infections therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Complicated Urinary Tract Infections